Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931682 · ClinicalTrials.gov registry record
Observational Study of Males With Creatine Transporter Deficiency
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 50
- Enrollment target
NCT02931682: Clinical Trial study, sponsored by Ultragenyx Pharmaceutical.
NCT02931682 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02931682 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-12 |
| Est. Completion | 2022-10-24 |
Why NCT02931682 stopped before completion
NCT02931682 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02931682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02931682 about?
NCT02931682 is a clinical study titled "Observational Study of Males With Creatine Transporter Deficiency". The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.
What is the current status of trial NCT02931682?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2016-12. Estimated completion is 2022-10-24.
Who is sponsoring clinical trial NCT02931682?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia